Clinical trial · Observational
Analysis of a New Biomarker for Prostate Cancer Diagnosis
NCT01819740CI-TRIAL-00009854HEMunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of our study is to determine if the levels of the "HEM" substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Patients With Suspected Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| determine the levels of the "HEM" substance in seminal plasma | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- patients with suspected prostate cancer
- interventionNames
- Other: determine the levels of the "HEM" substance in seminal plasma
Primary outcomes (1)
- measure
- substance "HEM" concentration in seminal plasma (mEq/L measured by spectro-photometry
- timeFrame
- 1 hour
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 45 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical or laboratory suspected of prostate cancer Exclusion Criteria: * Inability to ejaculate
References
Publications (0)
Data not yet available
No reference posted for this study.